Supplemental
Capital expenditures incurred but not yet paid
Alnylam Pharmaceuticals Capital expenditures incurred but not yet paid increased by 607.6% to $9.19M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 151.6%, from $3.65M to $9.19M.
Analysis
StatementCash Flow Statement
SectionSupplemental
First reportedQ1 2013
Last reportedQ1 2026Apr 30, 2026
Metric ID:
nflx_capex_incurred_not_paidHistorical Data
12 periods
| Q2 '21 | Q4 '21 | Q1 '22 | Q1 '23 | Q2 '23 | Q1 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.51M | $4.19M | $8.32M | $4.03M | $1.63M | $2.24M | $1.58M | $3.65M | $431.00K | $5.52M | $1.30M | $9.19M |
| QoQ Change | — | -7.1% | +98.8% | -51.5% | -59.6% | +37.6% | -29.4% | +130.7% | -88.2% | >999% | -76.5% | +607.6% |
| YoY Change | — | — | — | -51.5% | — | -44.4% | — | +62.8% | — | — | -18.0% | +151.6% |
Range$431.00K – $9.19M
CAGR+29.5%
Avg YoY Growth+20.1%
Median YoY Growth-18.0%
Capital expenditures incurred but not yet paid at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's capital expenditures incurred but not yet paid?
- Alnylam Pharmaceuticals (ALNY) reported capital expenditures incurred but not yet paid of $9.19M in Q1 2026.
- How has Alnylam Pharmaceuticals's capital expenditures incurred but not yet paid changed year-over-year?
- Alnylam Pharmaceuticals's capital expenditures incurred but not yet paid increased by 151.6% year-over-year, from $3.65M to $9.19M.